NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · MID CAP
Pacific Biosciences of California, Inc. PACB
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$160.0M
▲ 3.9% vs FY2024
EPS · FY25
$-1.82
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-213.5%
Net margin · FY25
-341.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 160.0M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 341 cents on every revenue dollar this year.
Per share
USD -1.82
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-213.5%
Return on equity, FY2025
ROE
Operating margin-346.2%
Net margin-341.5%
Return on assets-53.4%
Each USD of equity lost 213 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+15.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.6%
+15.2%
+5.6%
+35.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.30B
Shares outstanding, FY2025
Change, 5 years+57.0%
Change, 10 years+277.5%
The share count grew 57% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 784.1M
total assets, end of FY2025
Total assetsUSD 784.1M
EquityUSD 5.3M
CashUSD 63.7M
Current ratio5.15×
Equity funds 1% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.6
−0.5
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
·
·
EBITDA $B
−0.5
−0.5
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
·
·
Income tax $B
0.0
0.0
−0.0
0.0
−0.1
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.5
−0.3
−0.3
−0.3
−0.2
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−1.82
−1.59
−1.21
−1.40
−0.89
0.17
−0.55
−0.76
−0.87
−0.83
−0.42
−0.94
−1.26
−1.69
−2.03
−14.10
−173.03
Dividend / sh $
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−213.5
−51.3
−48.5
−46.4
−32.2
15.1
−99.6
−102.5
−108.0
−94.0
−49.3
−106.6
−88.8
−62.8
−46.4
−272.8
·
Shares out B
0.30
0.29
0.27
0.23
0.22
0.19
0.15
0.15
0.12
0.09
0.08
0.07
0.07
0.06
0.00
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
63 of 63
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed